Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease

Kidney International

Volumn 75, Issue 9, 2009, Pages 976-981

  Ashby, Damien R ^a   Gale, Daniel P ^a,b   Busbridge, Mark ^a   Murphy, Kevin G ^a   Duncan, Neill D ^a   Cairns, Tom D ^a   Taube, David H ^a   Bloom, Stephen R ^a   Tam, Frederick W K ^a   Chapman, Richard S ^a   Maxwell, Patrick H ^b   Choi, Peter ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEPCIDIN; INTERLEUKIN 6; IRON;

ADULT; ANEMIA; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; IRON THERAPY; KIDNEY DISEASE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRITINS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; YOUNG ADULT;

EID: 64949191416     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.21     Document Type: Article

References (31)

1. Macdougall IC, Tucker B, Thompson J et al A randomized controlled study of iron supplementation in patients treated with erythropoietin Kidney Int 1996; 50 1694-1699.
2. Zhang Y, Thamer M, Stefanik K et al Epoetin requirements predict mortality in hemodialysis patients Am J Kidney Dis 2004; 44 866-876.
3. Zager RA. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol 2006; 1(Suppl 1): S24-S31.
4. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 2006; 1(Suppl 1): S19-S23.
5. Valore EV, Ganz T Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin Blood Cells Mol Dis 2008; 40 132-138.
6. Nemeth E, Tuttle MS, Powelson J et al Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization Science 2004; 306 2090-2093.
7. Mazur A, Feillet-Coudray C, Romier B et al Dietary iron regulates hepatic hepcidin 1 and 2 mRNAs in mice Metabolism 2003; 52 1229-1231.
8. Nicolas G, Chauvet C, Viatte L et al The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation J Clin Invest 2002; 110 1037-1044.
9. Ganz T Iron homeostasis: fitting the puzzle pieces together Cell Metab 2008; 7 288-290.
10. Nicolas G, Bennoun M, Devaux I et al Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice Proc Natl Acad Sci USA 2001; 98 8780-8785.
11. Nemeth E, Preza GC, Jung CL et al The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study Blood 2006; 107 328-333.
12. Rivera S, Nemeth E, Gabayan V et al Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportincontaining organs Blood 2005; 106 2196-2199.
13. Park CH, Valore EV, Waring AJ et al Hepcidin, a urinary antimicrobial peptide synthesized in the liver J Biol Chem 2001; 276 7806-7810.
14. Swinkels DW, Girelli D, Laarakkers C et al Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry PLoS ONE 2008; 3 e2706.
15. Ganz T Molecular control of iron transport J Am Soc Nephrol 2007; 18 394-400.
16. Nemeth E, Rivera S, Gabayan V et al IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin J Clin Invest 2004; 113 1271-1276.
17. Hentze MW, Muckenthaler MU, Andrews NC Balancing acts: molecular control of mammalian iron metabolism Cell 2004; 117 285-297.
18. De Domenico I, Ward DM, Kaplan J Hepcidin regulation: ironing out the details J Clin Invest 2007; 117 1755-1758.
19. Ganz T Molecular pathogenesis of anemia of chronic disease Pediatr Blood Cancer 2006; 46 554-557.
20. Madore F, Lowrie EG, Brugnara C et al Anemia in hemodialysis patients: variables affecting this outcome predictor J Am Soc Nephrol 1997; 8 1921-1929.
21. Locatelli F, Andrulli S, Memoli B et al Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients Nephrol Dial Transplant 2006; 21 991-998.
22. Roe MA, Spinks C, Heath AL et al Serum prohepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women Br J Nutr 2007; 97 544-549.
23. Nemeth E, Valore EV, Territo M et al Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein Blood 2003; 101 2461-2463.
24. Kemna E, Tjalsma H, Laarakkers C et al Novel urine hepcidin assay by mass spectrometry Blood 2005; 106 3268-3270.
25. Pasqualetti P, Collacciani A, Casale R Circadian rhythm of serum erythropoietin in myelodysplastic syndromes Eur Rev Med Pharmacol Sci 2000; 4 111-115.
26. Eleftheriadis T, Kartsios C, Liakopoulos V et al. Does hepcidin affect erythropoiesis in hemodialysis patients? Acta Haematol 2006; 116: 238-244.
27. Swinkels DW, Wetzels JF. Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol Dial Transplant 2008; 23: 2450-2453.
28. Tanno T, Bhanu NV, Oneal PA et al High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin Nat Med 2007; 13 1096-1101.
29. Ganz T, Olbina G, Girelli D et al. Immunoassay for human serum hepcidin. Blood 2008.
30. Tomosugi N, Kawabata H, Wakatabe R et al Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System Blood 2006; 108 1381-1387.
31. Vokurka M, Krijt J, Sulc K et al Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis Physiol Res 2006; 55 667-674.